MRNA vs. ONC: A Head-to-Head Stock Comparison

Updated on October 7, 2025

Here’s a clear look at MRNA and ONC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

MRNA is a standard domestic listing, while ONC trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

Symbol	MRNA	ONC
Company Name	Moderna, Inc.	BeOne Medicines AG
Country	United States	Switzerland
GICS Sector	Health Care	Health Care
GICS Industry	Biotechnology	Biotechnology
Market Capitalization	11.08 billion USD	40.31 billion USD
Exchange	NasdaqGS	NasdaqGS
Listing Date	December 7, 2018	February 3, 2016
Security Type	Common Stock	ADR

Historical Performance

This chart compares the performance of MRNA and ONC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

MRNA vs. ONC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	MRNA	ONC
5-Day Price Return	12.48%	-0.90%
13-Week Price Return	-6.56%	32.50%
26-Week Price Return	0.49%	41.02%
52-Week Price Return	-54.89%	20.61%
Month-to-Date Return	10.30%	10.40%
Year-to-Date Return	-31.48%	90.60%
10-Day Avg. Volume	10.68M	4.56M
3-Month Avg. Volume	10.33M	4.05M
3-Month Volatility	53.98%	51.09%
Beta	1.11	0.78

Profitability

Return on Equity (TTM)

MRNA

-27.46%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

MRNA has a negative Return on Equity of -27.46%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ONC

-6.58%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

ONC has a negative Return on Equity of -6.58%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

MRNA vs. ONC: A comparison of their Return on Equity (TTM) against the Biotechnology industry benchmark.

Net Profit Margin (TTM)

MRNA

-94.31%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

MRNA has a negative Net Profit Margin of -94.31%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

ONC

-5.04%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

ONC has a negative Net Profit Margin of -5.04%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

MRNA vs. ONC: A comparison of their Net Profit Margin (TTM) against the Biotechnology industry benchmark.

Operating Profit Margin (TTM)

MRNA

-106.34%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

MRNA has a negative Operating Profit Margin of -106.34%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

ONC

-2.03%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

ONC has a negative Operating Profit Margin of -2.03%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

MRNA vs. ONC: A comparison of their Operating Profit Margin (TTM) against the Biotechnology industry benchmark.

Profitability at a Glance

Symbol	MRNA	ONC
Return on Equity (TTM)	-27.46%	-6.58%
Return on Assets (TTM)	-21.24%	-3.87%
Net Profit Margin (TTM)	-94.31%	-5.04%
Operating Profit Margin (TTM)	-106.34%	-2.03%
Gross Profit Margin (TTM)	68.32%	85.37%

Financial Strength

Current Ratio (MRQ)

MRNA

3.93

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

MRNA’s Current Ratio of 3.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

ONC

1.94

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

ONC’s Current Ratio of 1.94 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

MRNA vs. ONC: A comparison of their Current Ratio (MRQ) against the Biotechnology industry benchmark.

Debt-to-Equity Ratio (MRQ)

MRNA

0.01

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

MRNA’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ONC

0.27

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

ONC’s Debt-to-Equity Ratio of 0.27 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

MRNA vs. ONC: A comparison of their Debt-to-Equity Ratio (MRQ) against the Biotechnology industry benchmark.

Interest Coverage Ratio (TTM)

MRNA

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

Interest Coverage Ratio data for MRNA is currently unavailable.

ONC

-132.16

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

ONC has a negative Interest Coverage Ratio of -132.16. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

MRNA vs. ONC: A comparison of their Interest Coverage Ratio (TTM) against the Biotechnology industry benchmark.

Financial Strength at a Glance

Symbol	MRNA	ONC
Current Ratio (MRQ)	3.93	1.94
Quick Ratio (MRQ)	3.59	1.65
Debt-to-Equity Ratio (MRQ)	0.01	0.27
Interest Coverage Ratio (TTM)	--	-132.16

Growth

Revenue Growth

MRNA vs. ONC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

MRNA vs. ONC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

MRNA

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ONC

0.16%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ONC’s Dividend Yield of 0.16% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

MRNA vs. ONC: A comparison of their Dividend Yield (TTM) against the Biotechnology industry benchmark.

Dividend Payout Ratio (TTM)

MRNA

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ONC

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ONC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

MRNA vs. ONC: A comparison of their Dividend Payout Ratio (TTM) against the Biotechnology industry benchmark.

Dividend at a Glance

Symbol	MRNA	ONC
Dividend Yield (TTM)	0.00%	0.16%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

MRNA

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

P/E Ratio data for MRNA is currently unavailable.

ONC

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

P/E Ratio data for ONC is currently unavailable.

MRNA vs. ONC: A comparison of their Price-to-Earnings Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Sales Ratio (TTM)

MRNA

3.60

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 3.60 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

ONC

9.46

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

ONC’s P/S Ratio of 9.46 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

MRNA vs. ONC: A comparison of their Price-to-Sales Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Book Ratio (MRQ)

MRNA

1.14

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

MRNA’s P/B Ratio of 1.14 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

ONC

8.16

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

ONC’s P/B Ratio of 8.16 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

MRNA vs. ONC: A comparison of their Price-to-Book Ratio (MRQ) against the Biotechnology industry benchmark.

Valuation at a Glance

Symbol	MRNA	ONC
Price-to-Earnings Ratio (TTM)	--	--
Price-to-Sales Ratio (TTM)	3.60	9.46
Price-to-Book Ratio (MRQ)	1.14	8.16
Price-to-Free Cash Flow Ratio (TTM)	36.60	160.00